Antibodies or antigen-binding fragments thereof, methods of making and medical uses thereof
CN115298216BActive Publication Date: 2026-07-07SHANGHAI HANSOH BIOMEDICAL CO LTD +1
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHANGHAI HANSOH BIOMEDICAL CO LTD
- Filing Date
- 2021-04-15
- Publication Date
- 2026-07-07
AI Technical Summary
Technical Problem
The lack of existing antibodies that can specifically recognize and effectively inhibit GPC3 expression in cancer cells leads to poor cancer treatment outcomes.
Method used
An anti-GPC3 antibody or its antigen-binding fragment containing a specific CDR region sequence has been developed. When combined with humanized or chimeric antibodies, it enhances ADCC toxicity and is prepared by genetic engineering methods, making it suitable for the treatment of various cancers.
Benefits of technology
It achieved highly specific recognition and significant killing effect on GPC3-expressing cancer cells, significantly improving the effectiveness and safety of cancer treatment.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure PCTCN2021087549-APPB-000001 
Figure PCTCN2021087549-APPB-000002 
Figure PCTCN2021087549-APPB-000003
Abstract
Provided are antibodies or antigen-binding fragments thereof, methods of making the same, and medical uses thereof. In particular, provided are chimeric antibodies, humanized antibodies comprising CDR regions of anti-GPC3 antibodies, and pharmaceutical compositions comprising anti-GPC3 antibodies or antigen-binding fragments thereof, and uses thereof as anti-cancer drugs. In particular, provided is a humanized anti-GPC3 antibody, and uses thereof in the manufacture of a medicament for treating a GPC3-mediated disease or disorder, and in cell growth inhibition, and in tumor detection and diagnosis.
Need to check novelty before this filing date? Find Prior Art